Lantheus Receives CRL for LNTH-2501, Shares Drop 18%
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
lantheuslnth-2501
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Lantheus Holdings Inc. announced on June 26, 2026, that the U.S. Food and Drug Administration issued a Complete Response Letter for its New Drug Application for LNTH-2501. The regulatory action delays the potential commercial launch of the radiopharmaceutical candidate. Lantheus stock declined 18% in after-hours trading following the disclosure, erasing approximately $1.2 billion in market capitalization. The company stated the letter did not cite any clinical efficacy or safety issues but requested additional chemistry, manufacturing, and controls information.
Regulatory scrutiny of radiopharmaceutical manufacturing has intensified following recent industry developments. Novartis received a Form 483 for its radioligand therapy production facilities in January 2026, citing observations related to quality control. The current macro backdrop for biotech remains challenging, with the XBI Biotech Index down 4% year-to-date as the Fed funds rate holds at 5.25%. This event triggers a reassessment of regulatory timelines for a class of cancer drugs that attracted over $12 billion in venture capital funding since 2023.
The catalyst chain began with Lantheus submitting its NDA in the fourth quarter of 2025. The FDA's standard review cycle concluded with this Complete Response Letter rather than an approval. The agency's focus appears centered on production consistency and supply chain reliability for novel radioactive compounds. This reflects a broader regulatory shift toward ensuring strong manufacturing for complex therapeutics following several high-profile drug recalls in 2025.
Lantheus shares fell to $85.50 in extended trading, down 18% from Thursday's close of $104.25. The decline represents the stock's largest single-day drop since March 2023, when it fell 22% on clinical trial concerns. Trading volume surged to 4.8 million shares in after-hours sessions, nearly triple the 90-day average volume of 1.7 million shares. Market capitalization decreased from $6.8 billion to $5.6 billion based on the after-hours price movement.
The radiopharmaceutical sector underperformed the broader market following the news. The SPDR S&P Biotech ETF (XBI) declined 1.8% in after-hours trading, compared to the S&P 500's 0.2% decline. Peer company Point Biopharma Global Inc. fell 5.3%, while Novartis AG ADRs declined 1.2%. Lantheus's implied volatility measured 62% before the announcement, indicating options traders priced in significant event risk around the FDA decision.
The CRL creates near-term headwinds for Lantheus's revenue diversification beyond its diagnostic imaging business. Analysts projected LNTH-2501 could generate $350 million in peak annual sales if approved. Contract manufacturing organizations specializing in radiopharmaceuticals may face increased scrutiny, potentially delaying projects for clients like Blue Earth Diagnostics and Perspective Therapeutics. Companies with approved radiopharmaceuticals, including Novartis with Pluvicto, could benefit from reduced competitive pressure in the near term.
A counter-argument suggests the FDA's request for manufacturing information represents a solvable problem rather than a fundamental drug deficiency. Lantheus management emphasized the letter contained no requests for additional clinical studies. Hedge funds that were short the radiopharmaceutical sector covered portions of their positions during the after-hours decline, creating unusual volume patterns in related names. Long-only healthcare funds reduced exposure to mid-cap biotech names following the news.
Investors should monitor Lantheus's formal response timeline, expected within 90 days. The company will likely provide updated guidance during its Q2 earnings call scheduled for August 5, 2026. Key manufacturing partners like Curium Pharma may issue statements regarding production capacity and quality systems. The FDA's stance will become clearer when the agency reviews similar applications from Point Biopharma and ITM Soluciones in Q4 2026.
Technical levels for LNTH stock include support at $80, which held during the March 2023 selloff, and resistance at $95, representing the 50-day moving average. Approval of a competing radiopharmaceutical from another sponsor would signal whether the FDA's manufacturing concerns apply broadly to the sector or are specific to Lantheus's application. The VIX health care sector volatility index may remain elevated until regulatory clarity emerges.
A Complete Response Letter indicates the FDA has completed its review of a drug application but cannot approve it in its current form. The agency typically requests additional information, clinical data, or manufacturing changes before reconsidering approval. Unlike a outright rejection, a CRL often identifies specific, addressable deficiencies that the sponsor can resolve through further submission.
Lantheus continues generating revenue from established diagnostic products including DEFINITY ultrasound agent and PYLARIFY for prostate cancer imaging. These products produced $1.4 billion in revenue during fiscal year 2025. The delay of LNTH-2501 postpones but does not eliminate a potential revenue stream, allowing the company to maintain its current dividend policy while addressing FDA concerns.
Approximately 60% of drugs receiving Complete Response Letters eventually gain FDA approval according to data from 2018-2025. The approval timeline typically extends by 12-18 months as companies address the FDA's concerns. Therapeutic areas with unmet medical needs, including oncology, demonstrate higher ultimate approval rates compared to competitive drug classes with multiple treatment options.
The FDA's request for manufacturing data delays Lantheus's entry into the therapeutic radiopharmaceutical market.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.